Document ID: chunk:federal_register_of_legislation:F2018L00193:reg:9:p1
Version: federal_register_of_legislation:F2018L00193
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 3310–6312

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, toxic retinopathy or death from toxic retinopathy is connected with the circumstances of a person's relevant service:
(1)          being treated with a quinoline-based drug as specified, before the clinical onset of toxic retinopathy;
Note: being treated with a quinoline-based drug as specified is defined in the Schedule 1 - Dictionary.
(2)          being treated with tamoxifen as specified within the one year before the clinical onset of toxic retinopathy;
Note: being treated with tamoxifen as specified is defined in the Schedule 1 - Dictionary.
(3)          being treated with an intravitreal or subconjunctival aminoglycoside from the specified list of aminoglycosides, within the seven days before the clinical onset of toxic retinopathy;
Note: specified list of aminoglycosides is defined in the Schedule 1 - Dictionary.
(4)          being treated with intravitreal fomivirsen within the 30 days before the clinical onset of toxic retinopathy;
(5)          being treated with intravenous deferoxamine within the seven days before the clinical onset of toxic retinopathy;
(6)          being treated with the phenothiazine drugs chlorpromazine or thioridazine for a continuous period of at least the two weeks before the clinical onset of toxic retinopathy;
(7)          being treated with daily clofazimine, at an average dose of at least 100 milligrams per day, for a continuous period of at least the three months before the clinical onset of toxic retinopathy;
(8)          being treated with ritonavir for a continuous period of at least the three months before the clinical onset of toxic retinopathy;
(9)          being treated with interferon for a continuous period of at least four weeks, within the three months before the clinical onset of toxic retinopathy;
(10)      being treated with subcutaneous or intramuscular deferoxamine for a continuous period of at least the four weeks before the clinical onset of toxic retinopathy;
(11)      taking oral canthaxanthin supplements or tablets as specified within the five years before the clinical onset of toxic retinopathy;
Note: taking oral canthaxanthin supplements or tablets as specified is defined in the Schedule 1 - Dictionary.
(12)      inhaling isopropyl nitrite within the two weeks before the clinical onset of toxic retinopathy;
(13)      using an intravenous drug containing talc within the two years before the clinical onset of toxic retinopathy;
(14)      for cystoid macular oedema only:
(a)          being treated with daily niacin for a continuous period of at least two weeks, at an average dose of at least 1.5 grams per day, within the three months before the clinical onset of toxic retinopathy; or
(b)          being treated with intravenous paclitaxel or docetaxel within the three months before the clinical onset of toxic retinopathy;
Note: cystoid macular